Tamara Pukhalskaia

Dr. Tamara Pukhalskaia

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DBDaria Bogdanova
Daria Bogdanova
EKEkaterina Dmitrievna Kolosova
Ekaterina Dmitrievna Kolosova
TPTamara Pukhalskaia
Tamara Pukhalskaia
KLKsenia A. Levchuk
Ksenia A. Levchuk
Oleg DemidovOleg Demidov
Oleg Demidov
EBEkaterina Belotserkovskaya
Ekaterina Belotserkovskaya
The tumor microenvironment (TME) plays an essential role in tumor progression and in modulating tumor response to anticancer therapy. Cellular senescence leads to a switch in the cell secretome, characterized by the senescence-associated secretory phenotype (SASP), which may regulate tumorigenesis. Senolytic therapy is considered a novel anticancer strategy that eliminates the deleterious effects of senescent cells in the TME. Here, we show that two different types of senolytic drugs, despite efficiently depleting senescent cells, have opposite effects on cancer-associated fibroblasts (CAFs) and their ability to regulate epithelial–mesenchymal transition (EMT). We found that senolytic drugs, navitoclax and the combination of dasatinib/quercetin, reduced the number of spontaneously senescent and TNF-induced senescent CAFs. Despite the depletion of senescent cells, the combination of dasatinib/quercetin versus navitoclax increased the secretion of the SASP pro-inflammatory cytokine IL-6. This differential effect correlated with the promotion of enhanced migration and EMT in MC38 colorectal cancer cells. Our results demonstrate that some senolytics may have side effects unrelated to their senolytic activity and may promote tumorigenesis. We argue for more careful and extensive studies of the effects of senolytics on various aspects of tumor progression and tumor resistance to therapy before the senolytic strategy is implemented in the clinic.

23 July 2024 in Medical Immunology (Russia)
Verified
Journal Article
Open access
PDF file
TPTamara Pukhalskaia
Tamara Pukhalskaia
TYT. R. Yurakova
T. R. Yurakova
VMV. S. Mikhailovskaya
V. S. Mikhailovskaya
DBD. A. Bogdanova
D. A. Bogdanova
ODO. N. Demidov
O. N. Demidov
Tumor-associated macrophages (TAMs) are an important and most represented population of immune cells in the tumor microenvironment. To a great extent, TAMs can determine the direction of the antitumor immune response; they can either additionally stimulate it or on the contrary contribute to the formation of immunosuppressive microenvironment. At the same time, under the influence of tumor cells and antitumor therapy, many cells in the tumor microenvironment (TME) can develop a state of senescence. Over the last decade, the topic of senescence and the search for therapies aimed at removing senescent cells has gained popularity. In the search for new therapeutic strategies to treat cancer, senescent cells of the immune system in the tumor microenvironment have received special attention since the presence of senescent TAMs in tumors is associated with poor prognosis and poor response to therapy. Given the relevance of studying the role of senescent immune cells in TME (in particular tumor-associated macrophages), we performed a comparative analysis of experimental protocols to obtain tumor-associated macrophages in vitro to determine the most relevant approach. We tested two protocols for obtaining macrophages from mouse bone marrow: (1) by adding conditioned medium from the L929 mouse sarcoma cell line (LCCM) (LCCM-BMDM); and (2) by adding recombinant mouse M-CSF (M-CSF-BMDM). We showed that LCCM-BMDMs, compared to M-CSFBMDMs, have increased expression of the arginase enzyme (Arg1), which can inhibit the activity of anti-tumor cytotoxic lymphocytes by depleting arginine in the tumor microenvironment. LCCM-BMDMs also exhibited increased secretion of factors characteristic of the senescence-associated secretory phenotype (SASP): IL-6 and TNF. Both Arg1 and IL-6 and TNF are markers characteristic of senescence-associated macrophages. Thus, the use of LCCM to obtain primary macrophage culture limits further steps in creating a model of tumor-associated macrophages that reflects the specific characteristics of the macrophage phenotypic response for different tumor types aAnd also limits studies of senescence formation in tumor-associated macrophages in models of carcinogenesis other than sarcoma. We believe that differentiation of macrophages in the presence of M-CSF appears to be a more preferable protocol to study TAMs and senescent TAMs to test new therapeutic strategies.